RxDoctor Payments Data

Viji Meledath

Psychiatric/Mental Health · Westbury, NYNPI 1669962791

Payments from drug & device makers

$4,546in general payments, 2019–2025

Across 153 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lundbeck LLC$516
  • Alkermes, Inc.$344
  • E.r. Squibb & Sons, L.L.C.$333
  • Otsuka America Pharmaceutical, Inc.$181
  • plus $200 from 3 others

What the payments were for

  • Food & beverage$4,546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,546 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$338
Medicare patients
23
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$209,486
Abilify MaintenaAripiprazole38$99,806
Lurasidone Hcl22$26,448
Invega SustennaPaliperidone Palmitate11$25,889
Quetiapine Fumarate91$2,036
Divalproex Sodium ErDivalproex Sodium41$1,513
Fluphenazine Hcl11$661
Haloperidol Decanoate13$514
Mirtazapine57$478
Venlafaxine Hcl ErVenlafaxine Hcl35$470
Hydroxyzine Hcl74$469
Duloxetine Hcl40$435
Bupropion XlBupropion Hcl35$424
Olanzapine27$328
Fluoxetine Hcl55$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,950$209,48625 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$181$99,80638 claims
Johnson & JohnsonInvega Sustenna$79$25,88911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Westbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →